Business
RVX-208 Data Demonstrates Increase in Functional HDL Particles
Prebeta-HDL generation and improved HDL functionality are distinguishing factors TSX Exchange Sym...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nPrebeta-HDL generation and improved HDL functionality are distinguishing\nfactors\n\nTSX Exchange Symbol: RVX\n\n\nNEW ORLEANS, LA, Nov. 10 /CNW/ - Resverlogix Corp. ("Resverlogix")\n(TSX:RVX) is pleased to announce today key scientific data was presented in an\noral presentation highlighting the novel features of RVX-208 at the American\nHeart Association Scientific Meeting. The presentation titled "Compound\nRVX-208 Modulates HDL-C Levels and Function in Non-human Primates and in Early\nHuman Trials" was presented by Dr. Jacques Genest.\n\n\nDr. Jacques Genest, MD, Director of the Division of Cardiology at McGill\nUniversity Health Centre/Royal Victoria Hospital said, "We continue to be\nexcited about the data that is being generated for RVX-208. It is important\nthat our colleagues have access to this promising data which is why we have\npresented at this prominent conference. Resverlogix's novel drug demonstrated\nthe ability to increase the production of ApoA-I and functional HDL. Notably\nwe saw increases in prebeta-HDL particles, which improve HDL's ability to\nmediate cholesterol efflux."\n\n\n"Today we presented interesting and consistent data from African Green\nmonkey studies and our Phase 1a human clinical trial at the AHA," stated Dr.\nJan Johansson, MD, Ph.D., Senior Vice President, Medical Affairs of\nResverlogix. "The pharmacodynamic data from human healthy volunteers of which\nthe majority had low HDL demonstrated that we have seen significant increases\nin ApoA-I production and HDL functionality, consistent with previous findings\nin the African Green monkey studies. Further investigation of the effect of\nRVX-208 on the HDL metabolic pathway is ongoing in humans and animals to\nestablish the mechanisms of action and therapeutic potential in treating\natherosclerotic cardiovascular disease."\n\n\nDuring the presentation Dr. Genest reported that in an African Green\nmonkey study treatment with RVX-208 resulted in a highly significant increase\nin the average of serum ApoA-I and HDL-C levels (57% and 92%, respectively).\nIt was noted that RVX-208 treatment modified the distribution of HDL particle\nsize causing a significant increase in prebeta-HDL and the larger alpha-HDL\nparticles. The ability of serum to promote cholesterol efflux via ABCA1, ABCG1\nor ...